Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0034069 (pulmonary fibrosis)
 7,050 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An uncommon, but lethal, toxic side effect of busulfan (Myleran) therapy for chronic myelogenous leukemia is pulmonary fibrosis. A 16-month-old male infant treated for 11 months with busulfan for chronic myelogenous leukemia is, we believe, the first case of "busulfan lung" in the pediatric age group to be reported. Progressive roentgenographic changes in the lung of a diffuse intra-alveolar and interstitial pattern were noted. The patient died after a four-day episode of cough, fever, and progressive dyspnea. At autopsy, no evidence of infection or leukemic infiltrates were seen in the lungs. Characteristic histologic findings as a result of busulfan therapy were observed in the lung and pancreas.
 ...
PMID:Busulfan lung. 26 39

Autopsy findings from two patients who have been treated for several years with Busulfan because of chronic myelogenous leukemia are reported. Beside a pulmonary fibrosis epithelial dysplasias in the respiratory tract, the liver and kidney were detected. Furthermore, in one case beside a proliferation of reticulate cells in the spleen a distinct plasmocytosis of the bone marrow and a so-called "wasting syndrome" were found. The pathogenesis of these changes is still unkown; it may be that immunological processes play a role.
 ...
PMID:[Morphological findings after Busulfan long term therapy (author's transl)]. 82 30

Busulfan-induced diffuse interstitial pneumonia is a rare but serious disease attributed to a direct toxic effect of busulfan (an alkylating antimitotic drug) on alveolar cells. We report three new cases explored by repeated bronchoalveolar lavages and lung biopsies. All patients had circulating immune complexes, abnormalities at capillaroscopy and above all lymphocytic or mixed alveolitis at bronchoalveolar lavage. The clinical outcome was favourable with regression of the alveolar lesions in the patient with pure lymphocytic alveolitis. It was unfavourable in patients showing severe alveolitis with polymorphonuclear cells. Histology revealed constant abnormalities of type I pneumocytes and rarefaction of type II pneumocytes, together with interstitial oedema and pulmonary fibrosis in which tissue mast cells could not be identified. The immunological disturbances observed in busulfan lung might enhance an initial toxic reaction and account for the often unfavourable outcome, even after withdrawal of busulfan.
 ...
PMID:[Interstitial pneumopathies caused by busulfan. Histologic, developmental and bronchoalveolar lavage analysis of 3 cases]. 306 70